Trials / Completed
CompletedNCT05034926
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
A Multinational, Non-Interventional, Prospective Study of Nivolumab (BMS-936558) in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus - The 'Lucence' Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 212 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to estimate the overall survival (OS) rates in the overall study population treated with nivolumab in the second and third line setting in real world clinical practice in Greece and Cyprus. The study is descriptive in nature and is not planned to reject or affirm any formal statistical hypothesis.
Conditions
Timeline
- Start date
- 2020-10-07
- Primary completion
- 2025-10-31
- Completion
- 2025-10-31
- First posted
- 2021-09-05
- Last updated
- 2025-11-24
Locations
2 sites across 2 countries: Cyprus, Greece
Source: ClinicalTrials.gov record NCT05034926. Inclusion in this directory is not an endorsement.